AstraZeneca CEO Soriot On Obesity, Gene Therapy And More

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

CEO Pascal Soriot fielded questions on a wide range of topics – from China to US Medicare drug price negotiations – at a media briefing in New York City.

Pascal Soriot
AstraZeneca CEO Pascal Soriot • Source: AstraZeneca

One day after AstraZeneca PLC reported third quarter sales and earnings results and announced a licensing deal to bring in an oral glucagon-like peptide 1 (GLP-1) agonist for obesity, CEO Pascal Soriot outlined his thinking on the future of obesity drug development and how AstraZeneca might fit into what is expected to be a crowded market.

Key Takeaways

  • CEO Pascal Soriot discussed the company’s goals in obesity drug development and gene therapy R&D during a media briefing in New York.

During a media briefing in New York City on 10 November, Soriot commented on the new obesity deal as well...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.